<DOC>
	<DOCNO>NCT00002374</DOCNO>
	<brief_summary>To examine efficacy saquinavir SGC ( soft gel capsule ) combination antiretrovirals HIV-1 infect patient currently treat saquinavir HGC ( hard gel capsule ) measure absolute change plasma HIV-1 RNA 24 week study treatment .</brief_summary>
	<brief_title>A Study Saquinavir Soft Gelatin Capsules Combined With Other Anti-HIV Drugs HIV-1 Infected Patients</brief_title>
	<detailed_description>Eligible patient stratify HIV-1 RNA level 2 population : 1 ) &gt; = 5,000-30,000 HIV-1 RNA , 2 ) &gt; 30,000 HIV-1 RNA . All patient randomize 1 3 treatment arm : Arm A - Saquinavir soft gel capsule ( SQV SGC ) + 2 new nucleoside analog ( reverse transcriptase inhibitor [ RTIs ] ) , Arm B - SQV SGC + nelfinavir + stavudine ( d4T ) new RTI , Arm C - SQV SGC + ritonavir + d4T new RTI . All patient undergo plasma HIV-1 RNA determination , CD4 lymphocyte count , hematology chemistry blood work baseline , week 4 , 8 , 12 , 16 24 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Saquinavir</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<criteria>Inclusion Criteria Patients must : Documented HIV infection . CD4 &gt; 100 cells/mm3 . Saquinavir HGCexperienced patient ( &gt; = 3 month cumulative therapy ) . Required : &gt; = 3 month cumulative saquinavir HGC therapy .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1997</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>RNA , Viral</keyword>
	<keyword>Saquinavir</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>